REGENXBIO Inc. - Common Stock (RGNX)
Frequently Asked Questions About REGENXBIO Inc. - Common Stock (RGNX)
Does REGENXBIO have any collaborations with other companies?
Yes, REGENXBIO has established collaborations with various companies to leverage its AAV technology, including partnerships with AveXis and AbbVie to advance gene therapies targeting specific diseases.
How can investors learn more about REGENXBIO?
Investors can learn more about REGENXBIO by visiting the official company website, reviewing investor relations materials, and following updates through financial news outlets and stock market platforms.
How does REGENXBIO ensure the safety and efficacy of its therapies?
REGENXBIO ensures the safety and efficacy of its therapies through rigorous preclinical studies and clinical trials, adhering to regulatory standards set by the FDA and other authorities.
How does REGENXBIO's gene therapy work?
REGENXBIO's gene therapy works by introducing a healthy copy of a gene into a patient's cells using AAV vectors. This process aims to correct the underlying genetic defect and enable cells to produce functioning proteins, thus restoring normal cellular function.
Is REGENXBIO publicly traded?
Yes, REGENXBIO is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol RGNX, which allows investors to buy and sell shares of the company.
What are the company's key milestones?
Key milestones for REGENXBIO include successful clinical trial results, regulatory approvals for its product candidates, and partnerships that enhance its research and development efforts.
What challenges does REGENXBIO face?
REGENXBIO faces challenges typical of the biotech industry, including competition from other companies, the complexity of clinical trials, securing regulatory approvals, and the need for ongoing capital investment to fund research and development.
What does REGENXBIO Inc. do?
REGENXBIO Inc. is a biotechnology company focused on gene therapy, utilizing its proprietary AAV (adeno-associated virus) gene delivery platform to develop innovative therapies for various diseases, particularly those affecting the central nervous system, retina, and liver.
What is RGX-314 designed to treat?
RGX-314 is designed to treat wet age-related macular degeneration (AMD), a leading cause of vision loss in adults, by delivering a therapeutic gene that promotes long-term production of a protein to inhibit abnormal blood vessel growth in the retina.
What is the AAV delivery platform?
The AAV delivery platform is a core technology of REGENXBIO, employing adeno-associated viruses as vectors to deliver therapeutic genes to targeted cells, allowing for long-lasting effects with a single administration in various tissues.
What is the future outlook for REGENXBIO?
The future outlook for REGENXBIO appears promising, as the company continues to advance its clinical pipeline, initiate new clinical trials, and explore innovative applications of its gene therapy technology.
What is the significance of gene therapy?
Gene therapy is significant because it has the potential to address the root cause of genetic disorders by correcting or replacing defective genes, offering hope for patients suffering from previously untreatable conditions.
What is the status of REGENXBIO's lead product candidates?
REGENXBIO's lead product candidates include RGX-314 for wet age-related macular degeneration (AMD) and RGX-121 for Mucopolysaccharidosis Type II (MPS II), both of which are in various stages of clinical trials.
What therapeutic areas does REGENXBIO focus on?
REGENXBIO primarily focuses on developing gene therapies for conditions that affect the central nervous system, ocular diseases, metabolic disorders, and degenerative diseases, aiming to address high unmet medical needs in these areas.
What type of funding has REGENXBIO received?
REGENXBIO has raised significant funding through public offerings, private placements, and strategic partnerships, providing the necessary capital to support its research and development efforts.
What types of partnerships does REGENXBIO engage in?
REGENXBIO engages in strategic partnerships with other biotech and pharmaceutical companies, academic institutions, and research organizations to enhance its gene therapy programs and expand its development capabilities.
When was REGENXBIO founded?
REGENXBIO was founded in 2013, and since its inception, the company has been dedicated to advancing gene therapy as a transformative treatment option for patients with genetic diseases.
Where is REGENXBIO headquartered?
REGENXBIO is headquartered in Rockville, Maryland, USA, strategically located in proximity to key biotech hubs and regulatory agencies.
Who are the key executives at REGENXBIO?
REGENXBIO's leadership team includes Nicolas A. Kitchin, CEO, and other experienced professionals in the biotechnology and pharma industries, who bring a wealth of knowledge and expertise to the company.
What is the current price of REGENXBIO Inc. - Common Stock?
The current price of REGENXBIO Inc. - Common Stock is 6.670
When was REGENXBIO Inc. - Common Stock last traded?
The last trade of REGENXBIO Inc. - Common Stock was at 4:00 pm EDT on April 3rd, 2025
What is the market capitalization of REGENXBIO Inc. - Common Stock?
The market capitalization of REGENXBIO Inc. - Common Stock is 289.92M
How many shares of REGENXBIO Inc. - Common Stock are outstanding?
REGENXBIO Inc. - Common Stock has 43.47M shares outstanding.